Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab open-label extension in heterozygous familial hypercholesterolemia
NL-OMON45050Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Sanofi. Primary endpoint: Long-term safety. Started Feb 2014; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON45050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45050.